ITM Isotopen Technologien München Overview

  • Founded
  • 2004

Founded
  • Status
  • Private

  • Employees
  • 350

Employees
  • Latest Deal Type
  • Corporate

  • Financing Rounds
  • 7

  • Investments
  • 2

ITM Isotopen Technologien München General Information

Description

Operator of a radiopharmaceutical biotech company intended to improve the treatment outcome of cancer patients. The company offers medical radioisotopes, a new generation of targeted cancer diagnostics and therapies, precision oncology technologies to patients, therapeutic radiopharmaceuticals clinicians and healthcare partners, enabling nuclear medicine to reach its full potential for helping patients live longer and better.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Walther-von-Dyck-Strasse 4
  • 85748 Munich
  • Germany
+49 089 0000000000

ITM Isotopen Technologien München Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ITM Isotopen Technologien München Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ITM Isotopen Technologien München‘s full profile, request access.

Request a free trial

ITM Isotopen Technologien München Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a radiopharmaceutical biotech company intended to improve the treatment outcome of cancer patients. The comp
Diagnostic Equipment
Munich, Germany
350 As of 2022
00000
000000000000 00000

000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut e
000000000000000
Saint-Genis-Pouilly, France
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000

000000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
0000 000000000
Barcelona, Spain
00 As of 0000
0000
000000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ITM Isotopen Technologien München Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Advanced Accelerator Applications Formerly VC-backed Saint-Genis-Pouilly, France 000 00000 000000&0 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
0000 (000000000000 Corporation West Chester, PA 0000000000
0000000 0000000000 Corporation Dublin, OH 00 000.00 000000000 000.00
0000000 0000000000 Formerly VC-backed Eveleigh, Australia 00 00000 00000000 00000
You’re viewing 5 of 13 competitors. Get the full list »

ITM Isotopen Technologien München Patents

ITM Isotopen Technologien München Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102021109246-B3 Radiopharmaceuticals to different arts Active 13-Apr-2021 0000000000 0
AU-2020268836-A1 Para-aminohippuric acid (pah) as a renal protective substance Pending 08-May-2019 00000000000
CA-3135331-A1 Para-aminohippuric acid (pah) as a renal protective substance Pending 08-May-2019 00000000000
EP-3965751-A1 Para-aminohippuric acid (pah) as a renal protective substance Pending 08-May-2019 00000000000
CA-3054925-A1 Method for the manufacture of highly purified 68ge material for radiopharmaceutical purposes Pending 10-May-2017 C01G17/003
To view ITM Isotopen Technologien München’s complete patent history, request access »

ITM Isotopen Technologien München Executive Team (11)

Name Title Board Seat Contact Info
Steffen Schuster Chief Executive Officer
Klaus Maleck Ph.D Chief Financial Officer
Mark Harfensteller Ph.D Chief Operating Officer & Managing Director, ITM Medical Isotopes
Konstantin Zhernosekov Ph.D Chief Scientific Officer, Managing Director ITM Medical Isotopes & ITM Oncologics
Sebastian Marx Ph.D Chief Business Officer & Managing Director ITM Pharma Solutions
You’re viewing 5 of 11 executive team members. Get the full list »

ITM Isotopen Technologien München Board Members (3)

Name Representing Role Since
000000 0000 ITM Isotopen Technologien München Founder, Supervisory Board Member & Advisor to the CEO 000 0000
0000 000000 Self Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

ITM Isotopen Technologien München Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ITM Isotopen Technologien München Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ITM Isotopen Technologien München‘s full profile, request access.

Request a free trial

ITM Isotopen Technologien München Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 18-Aug-2022 0000000000 Other Healthcare Technology Systems 0000000 0
Joint Venture (Chengdu Gaotong Isotope / ITM) 13-Sep-2021 Joint Venture Pharmaceuticals 0000000 0
To view ITM Isotopen Technologien München’s complete investments history, request access »